Champions Oncolog Cmn (CSBR) 1.99 $CSBR Champions

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Champions Oncolog Cmn (CSBR) 1.99 $CSBR

Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year
PR Newswire - Thu Jul 28, 7:00AM CDT
Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2016.
CSBR: 1.99 (+0.17)

Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Jun 15, 11:00AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the closing of its previously announced underwritten public offering of 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, the Company announced today the partial exercise of the over-allotment option granted to the underwriter to purchase an additional 258,749 shares of its common stock at the public offering price. All of the shares have been offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)

Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Thu Jun 09, 6:30PM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), or the "Company", a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the pricing of its previously announced underwritten public offering. The Company is offering 2,000,000 registered shares of its common stock, par value $0.001 per share, at an offering price of $2.25 per share. In addition, Champions Oncology, Inc. has granted the underwriter a 45-day over-allotment option to purchase up to 300,000 additional shares of common stock at the public offering price. All of the shares are being offered by the Company. The shares of Champions Oncology, Inc. are currently trading on NASDAQ under the symbol "CSBR".
CSBR: 1.99 (+0.17), NHLD: 3.12 (+0.02)

Champions Oncology Announces Addition to Board of Directors
PR Newswire - Tue Apr 12, 11:30AM CDT
Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more than 30 years of experience in oncology. His appointment will further the company's efforts to accelerate growth and increase the adoption of its technology platform.
CSBR: 1.99 (+0.17)

Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016
PR Newswire - Tue Mar 15, 7:30AM CDT
Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2016.
CSBR: 1.99 (+0.17)

Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016
PR Newswire - Fri Mar 11, 8:00AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will be presenting at the 28th Annual ROTH Capital Conference on Wednesday, March 16, 2016. The Conference will be held at the Ritz Carlton in Dana Point, California from March 13 - 16, 2016.
CSBR: 1.99 (+0.17)

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016
PR Newswire - Thu Mar 10, 9:00AM CST
Champions Oncology (NASDAQ: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2016, on Tuesday, March 15, 2016, before the market open.
CSBR: 1.99 (+0.17)

Champions Oncology begins prospective correlative trial in sarcoma patients
M2 - Fri Jan 22, 3:09AM CST
Oncology drug company Champions Oncology (NasdaqCM:CSBR) disclosed on Thursday theat it has launched a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma.
CSBR: 1.99 (+0.17)

Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma
PR Newswire - Thu Jan 21, 10:00AM CST
Champions Oncology (NASDAQ:CSBR) today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft® PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.
CSBR: 1.99 (+0.17)

Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015
PR Newswire - Mon Dec 14, 3:50PM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second quarter ended October 31, 2015.
CSBR: 1.99 (+0.17)

Champions Oncology Signs Deal to Expand Technology Platform into AML
PR Newswire - Mon Dec 14, 3:01PM CST
Champions Oncology, Inc. (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it signed an agreement with a top 20 global pharmaceutical company to develop a novel process for establishing hematology models. The initial agreement will provide near-term revenue for the Company, as well as result in a longer-term revenue growth stream.
CSBR: 1.99 (+0.17)

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 14, 2015
PR Newswire - Thu Dec 10, 9:45AM CST
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2015, on Monday, December 14, 2015, after the market close.
CSBR: 1.99 (+0.17)

Champions Oncology to Present at LD MICRO Investor Conference
PR Newswire - Mon Nov 30, 10:51AM CST
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that Joel Ackerman, Chief Executive Officer, will be presenting at the LD MICRO Investor Conference on Wednesday, December 2, 2015 at 4:30pm Pacific Standard Time (PST). The conference, held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA, will feature 200 small/micro-cap companies and is expected to host more than 1,000 portfolio managers, research analysts and other investors.
CSBR: 1.99 (+0.17)

Champions Oncology Reports Results for the First Quarter Ended July 31, 2015
PR Newswire - Thu Sep 10, 3:05PM CDT
Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2015.
CSBR: 1.99 (+0.17)

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2015
PR Newswire - Tue Sep 08, 9:30AM CDT
Champions Oncology (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2015, on Thursday, September 10, 2015, after the market close.
CSBR: 1.99 (+0.17)

Champions Oncology files two patents with USPTO for use of PDX platform in immune-oncology
M2 - Tue Aug 18, 3:01AM CDT
Oncology drugs company Champions Oncology (OtherOTC:CSBR) disclosed on Monday that it has submitted two patent applications to the US Patent and Trademark Office (USPTO) with respect to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines with its Champions TumorGraft platform.
CSBR: 1.99 (+0.17)

Champions Oncology Files Patents for Use of PDX Platform in Immune-Oncology
PR Newswire - Mon Aug 17, 8:11AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it has filed two patent applications with the United States Patent and Trademark Office (USPTO) relating to the development and use of mice with humanized immune systems to test immune-oncology drugs and therapeutic cancer vaccines.
CSBR: 1.99 (+0.17)

/C O R R E C T I O N -- Champions Oncology, Inc./
PR Newswire - Wed Aug 12, 8:25AM CDT
In the news release, Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ, issued 12-Aug-2015 by Champions Oncology, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "August 12, 2015" rather than "August 10, 2015" as originally issued inadvertently. The complete, corrected release follows:
CSBR: 1.99 (+0.17)

Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ
PR Newswire - Wed Aug 12, 7:00AM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 1-for-12 reverse stock split of the Company's authorized, issued and outstanding common stock. The reverse stock split is in preparation for the Company's proposed listing of its common stock on the NASDAQ Capital Market. The company's common stock will begin trading on a post-split basis at the opening of trading on August 10, 2015.
CSBR: 1.99 (+0.17)

Champion Oncology Announces Additions to Leadership Team to Support Continued Growth
PR Newswire - Wed Aug 05, 1:00PM CDT
Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that David DeOrnellis joined the organization as Global Director of Laboratory Operations; Mark Weinstein assumed the role of Chief Information Officer; and Jordan Rubinson was named Chief Commercial Officer.
CSBR: 1.99 (+0.17), NVS: 81.34 (-0.60)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 41

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 92

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 114

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Brave Healer Productions Unveils Transformational Book Series

Updated Category News Views 253

Brave Healer Productions Unveils Transformational Book Series Brave Healer Productions has made an exciting announcement with the introduction of Shaman Heart: We Are the Ones We've Been Waiting For, the third volume in the acclaimed Shaman Heart series. This significant release highlights the wisdom of 26 courageous healers, teachers, and spiritual mentors who embarked...

Continue Reading
Empowering Fans: Miss Universe Adopts Blockchain Voting App

Updated Category News Views 314

Revolutionizing Fan Engagement with Blockchain Technology In a historical move that blends tradition with technology, the Miss Universe Organization (MUO) has partnered with Zetrix to unveil the Miss Universe Global Blockchain Voting App. This strategic alliance aims to empower fans worldwide by facilitating secure and trustworthy voting experiences, marking a significant...

Continue Reading
Occidental Bets Big on Argentine Sunflower Boom

Updated Category News Views 64

The Sunflower Seed Gamble When a company like Occidental Resources plunks down $200 million for sunflower seeds, you sit up and take notice. We're talking 300,000 metric tons of those little yellow gems sourced from Argentina, which according to the Rosario Board of Trade, is rolling in a whopping 6.6 million metric tons of sunflower product this year. Doesn't sound like...

Continue Reading
Martini Market’s $MRT Presale: Last Chance to Seize the Opportunity

Updated Category News Views 207

The Exciting Conclusion of the Martini Market Presale As the highly anticipated $MRT token presale approaches its final days, the excitement is palpable in the decentralized finance (DeFi) community. With just a few days left, Martini Market has established itself as a frontrunner in the realm of decentralized prediction markets on the XRP Ledger. What Makes Martini...

Continue Reading
Samsara Intelligence: Transforming Operations with AI Power

Updated Category News Views 345

Revolutionizing Operations with Samsara Intelligence Samsara Inc. (NYSE: IOT), a trailblazer in the Connected Operations Cloud space, has just launched Samsara Intelligence. This sophisticated suite of AI offerings is crafted to assist businesses in making informed decisions, thereby streamlining operations while ensuring safety. Harnessing an extensive database that...

Continue Reading